Pekka Taimen
MD, PhD
pepeta@utu.fi +358 29 450 4524 +358 50 431 1353 Kiinamyllynkatu 10 Turku Työhuone: D5019 ORCID-tunniste: https://orcid.org/0000-0001-8849-4604 Official web page of research group |
pathology; histology; cell biology; prostate cancer, bladder cancer, cardiomyopathy, nuclear lamin
Pekka Taimen received his MD degree from the University of Turku in 2001 and defended his thesis at the Department of Pathology, University of Turku in 2004. In 2008-2009 PT worked as a postdoctoral fellow in the laboratory of Prof. Robert D. Goldman, Northwestern University Medical School, Chicago. Postdoctoral studies focusing on nuclear intermediate filament proteins called lamins were further continued as a junior group leader after returning back to Turku in early 2010. In 2011 PT received a specialist degree in Pathology and since then he has worked as a part-time specialist at the Pathology Division, Turku University Hospital with special focus on uropathology. From 2012 PT has worked as a Clinical lecturer in Pathology and between 2015-2019 as a part-time Academy of Finland Clinical Researcher. PT was appointed as a tenure track Assistant Professor of Molecular Pathology in January 2019 and an Associate Professor in August 2020. In January 2022, PT was appointed as a Professor of Molecular Pathology and he currently serves as the head of the pathology unit at the Faculty of Medicine, University of Turku.
Professor Pekka Taimen has 20 years of experience in cell and molecular biology as well as in translational research. The main focus of his research group is on human diseases caused by lamin mutations, such as cardiomyopathies and premature aging syndrome. More recently, PT has also actively worked on prostate and bladder cancer related projects including novel biomarkers, biobanking, patient derived cell lines and improved imaging techniques utilizing digital pathology and machine learning approaches.
Pekka Taimen has more than 10 years of experience in teaching medical students at the Institute of Biomedicine, University of Turku. He has served first as a university teacher and from 2012 as a clinical lecturer. In 2015 PT received the Lecturer of the Year award in the Faculty of Medicine.
- PP2A methylesterase PME-1 suppresses anoikis and is associated with therapy relapse of PTEN-deficient prostate cancers (2023)
- Molecular Oncology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Prostate cancer detection and segmentation on MRI using non-local mask R-CNN with histopathological ground truth (2023)
- Medical Physics
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - STAT5b is a key effector of NRG-1/ERBB4-mediated myocardial growth (2023)
- EMBO Reports
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Transcripts of the Prostate Cancer-Associated Gene ANO7 Are Retained in the Nuclei of Prostatic Epithelial Cells (2023)
- International Journal of Molecular Sciences
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Value of 68Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [18F]fluoromethylcholine PET-CT and multiparametric MRI—a phase I/II study (2023)
- European Radiology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Actin-microtubule cytoskeletal interplay mediated by MRTF-A/SRF signaling promotes dilated cardiomyopathy caused by LMNA mutations (2022)
- Nature Communications
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - A heterozygous p.S143P mutation in LMNA associates with proteasome dysfunction and enhanced autophagy-mediated degradation of mutant lamins A and C (2022)
- Frontiers in cell and developmental biology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Comprehensive genomic profiling of Finnish lung adenocarcinoma cohort reveals high clinical actionability and SMARCA4 altered tumors with variable histology and poor prognosis (2022)
- Neoplasia
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Detection of Prostate Cancer Using Biparametric Prostate MRI, Radiomics, and Kallikreins: A Retrospective Multicenter Study of Men With a Clinical Suspicion of Prostate Cancer (2022)
- Journal of Magnetic Resonance Imaging
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Evolving imaging methods of prostate cancer and the emergence of magnetic resonance imaging guided ablation techniques (2022)
- Frontiers in Oncology
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - Increased Expression and Altered Cellular Localization of Fibroblast Growth Factor Receptor-Like 1 (FGFRL1) Are Associated with Prostate Cancer Progression (2022)
- Cancers
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD V.2.0) (2022)
- BMJ Open
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12-month clinical outcomes of a phase I study (2022)
- BJU International
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Preclinical Evaluation of a Humanized Antibody Against Common Lymphatic Endothelial and Vascular Endothelial Receptor-1, 89Zr-Desferrioxamine-Bexmarilimab, in a Rabbit Model of Renal Fibrosis (2022)
- Journal of Nuclear Medicine
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging–detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score (2022)
- European Urology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator (2022)
- European Urology Open Science
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource (2022)
- Cancer Epidemiology, Biomarkers and Prevention
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - The variant rs77559646 associated with aggressive prostate cancer disrupts ANO7 mRNA splicing and protein expression (2022)
- Human Molecular Genetics
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Uptake of 18F-rhPSMA-7.3 in Positron Emission Tomography Imaging of Prostate Cancer: A Phase 1 Proof-of-Concept Study (2022)
- Cancer Biotherapy and Radiopharmaceuticals
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Accurate Prostate Cancer Detection and Segmentation Using Non-Local Mask R-CNN With Histopathological Ground Truth (2021)
- International Journal of Radiation Oncology - Biology - Physics
(O2 Muu julkaisu )